Benchmark analyst Robert Wasserman raised the firm’s price target on Halozyme (HALO) to $68 from $55 and keeps a Buy rating on the shares on growing earnings momentum as well as anticipation of pending U.S. approval of Argenx’s (ARGX) subcutaneous Vyvgart for generalized Myasthenia Gravis, or gMG.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HALO: